The purpose of this symposium was to:
- Discuss the interplay between the coagulation cascade and platelets in arterial thrombus formation.
- Present the rationale for oral antiplatelet and anticoagulant therapy to reduce residual thrombotic risk in patients following Acute Coronary Syndrome (ACS).
- Discuss the significant benefits seen in patients following ACS when combining rivaroxaban 2.5 mg twice daily with standard antiplatelet therapy.
- Assess how the use of oral anticoagulation may change current standards of care and influence guidelines in patients with ACS.
Please view the full content in the pdf above.